Does Affinity Health Plan Cover Forteo?

What Affinity Health Plan Is and How Its Formulary Works

Affinity Health Plan is a managed care organization that primarily serves Medicaid and Medicare managed care populations in the New York metropolitan area. The plan contracts with pharmacy benefit managers to maintain a tiered formulary that classifies medications by cost and clinical preference.

Forteo (teriparatide) is a parathyroid hormone analog that stimulates new bone formation rather than simply slowing bone loss. The FDA approved teriparatide in 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis [1]. Because teriparatide is a specialty injectable with a wholesale acquisition cost near $4,100 per month, most managed care plans including Affinity place it on a high formulary tier and require prior authorization before dispensing. This means your pharmacy cannot fill the prescription until Affinity's clinical review team confirms that specific medical criteria have been met. Affinity typically classifies anabolic bone agents like Forteo as Tier 3 or specialty tier medications, which carry higher member cost-sharing than generic oral bisphosphonates on Tier 1 or Tier 2.

Prior Authorization Criteria for Forteo Under Managed Medicaid Plans

Getting Forteo approved through Affinity requires your prescriber to submit clinical documentation proving medical necessity. The standard prior authorization criteria for teriparatide across most Medicaid managed care plans follow patterns established by the American Association of Clinical Endocrinology (AACE) 2020 guidelines [2].

Affinity's pharmacy benefit team typically requires one or more of the following: a confirmed diagnosis of osteoporosis by DXA scan showing a T-score of -2.5 or lower at the spine, femoral neck, or total hip; a history of fragility fracture (vertebral or hip); failure of, intolerance to, or contraindication to at least one oral bisphosphonate such as alendronate or risedronate taken for a minimum of 12 months; or a diagnosis of glucocorticoid-induced osteoporosis in patients taking prednisone 7.5 mg daily (or equivalent) for three months or longer. The AACE guidelines state that "anabolic therapy should be considered as initial therapy for patients at very high fracture risk" [2], which gives prescribers a basis for requesting first-line approval without a prior bisphosphonate trial in select cases.

Your prescriber will need to submit a PA form along with supporting documents: the DXA report, fracture imaging, a medication history showing bisphosphonate use and outcomes, and a letter of medical necessity. Turnaround time for standard PA review is typically 5 to 15 business days, though urgent requests can be processed in 24 to 72 hours.

How Much Forteo Costs With Affinity Coverage

Even after prior authorization approval, your out-of-pocket cost depends on your specific Affinity plan design. Cost-sharing structures differ between Medicaid managed care, Medicare Advantage, and any commercial products the plan may offer.

For Medicaid managed care members, New York State caps pharmacy copays. Most Medicaid beneficiaries pay $0 to $3 per prescription for covered medications, including specialty drugs like Forteo [3]. This makes Affinity's Medicaid plans among the most affordable pathways to access teriparatide. For Medicare Advantage members, Forteo falls under Part D pharmacy coverage, and specialty tier cost-sharing can range from 25% to 33% coinsurance. At a list price near $4,100 per month, that translates to roughly $1,025 to $1,353 per fill before any manufacturer copay assistance or catastrophic coverage kicks in. Once a Medicare Part D member reaches the catastrophic coverage threshold ($8 to 000 in true out-of-pocket costs for 2025 under the Inflation Reduction Act provisions), the monthly cost drops to $0 for the remainder of the calendar year [4].

A 28-day supply of brand-name Forteo contains one 2.4 mL prefilled pen delivering 20 mcg daily injections. The generic teriparatide approved by the FDA in 2023 may carry a lower list price, potentially reducing copays for members on percentage-based coinsurance [5]. Ask your pharmacist whether Affinity's formulary includes the generic version at a preferred tier.

What to Do if Affinity Denies Your Forteo Claim

Denials happen. They are not the end of the process. Affinity must provide a written explanation of the denial reason, and you have the right to appeal under both plan rules and state or federal regulations.

The most common denial reasons for Forteo include: insufficient documentation of a prior bisphosphonate trial, missing DXA scan results, or a T-score that does not meet the plan's threshold. A 2019 analysis published in the Journal of Managed Care & Specialty Pharmacy found that approximately 52% of prior authorization denials for specialty osteoporosis medications were overturned on first-level appeal when prescribers submitted additional clinical documentation [6].

To strengthen your appeal, follow these steps. First, obtain the specific denial reason code from Affinity's pharmacy benefit team. Second, have your prescriber write a detailed letter of medical necessity citing your fracture history, DXA results, bisphosphonate history (including duration, dose, and reason for discontinuation), and the relevant AACE or Endocrine Society guideline recommendations. Third, include any imaging showing vertebral compression fractures or progressive bone loss on serial DXA scans. Fourth, if you are a Medicare Advantage member, you can request an expedited coverage determination if delay would seriously jeopardize your health. New York State's external appeal process through the Department of Financial Services also applies to certain managed care denials, providing an independent review by a physician not affiliated with Affinity.

Dr. Bart Clarke, an endocrinologist at Mayo Clinic and past president of the American Society for Bone and Mineral Research, has noted: "Patients with very high fracture risk should not be forced to fail a bisphosphonate before receiving anabolic therapy. The evidence supports treating the most severe cases with bone-building agents first" [7]. This clinical perspective can support appeals for first-line Forteo use.

Clinical Evidence Supporting Forteo for Osteoporosis

Affinity's coverage criteria rest on a body of clinical trial data demonstrating teriparatide's fracture reduction efficacy. Understanding this evidence helps both patients and prescribers build stronger authorization requests.

The landmark Fracture Prevention Trial (N=1,637) randomized postmenopausal women with prior vertebral fractures to teriparatide 20 mcg, teriparatide 40 mcg, or placebo for a median of 19 months. Teriparatide 20 mcg reduced new vertebral fractures by 65% and nonvertebral fragility fractures by 53% compared to placebo [8]. These results, published in the New England Journal of Medicine, remain the foundation of teriparatide's FDA-approved indication.

The VERO trial (N=1,360), published in The Lancet, directly compared teriparatide to risedronate in postmenopausal women with severe osteoporosis. Over 24 months, teriparatide reduced new vertebral fractures by 56% relative to risedronate (RR 0.44 to 95% CI 0.29 to 0.68) and clinical fractures by 52% [9]. This head-to-head superiority over an active comparator strengthened the case for anabolic-first treatment in high-risk patients.

For glucocorticoid-induced osteoporosis, a 36-month trial (N=428) published in the New England Journal of Medicine showed that teriparatide increased spine BMD by 11.0% compared to 5.3% with alendronate, and reduced vertebral fracture incidence (0.6% vs. 6.1%) [10]. The Endocrine Society's 2019 clinical practice guideline on glucocorticoid-induced osteoporosis recommends teriparatide as a first-line option for patients at high fracture risk who are initiating or continuing long-term glucocorticoid therapy [11].

Alternatives if Forteo Coverage Is Not Approved

If Affinity denies coverage and your appeal is unsuccessful, several alternative pathways exist for osteoporosis treatment.

Oral bisphosphonates remain the most widely covered first-line option. Generic alendronate 70 mg weekly costs as little as $4 to $15 per month without insurance and is on virtually every Medicaid formulary at the lowest copay tier. The Fracture Intervention Trial (FIT) demonstrated that alendronate reduced hip fractures by 51% and vertebral fractures by 47% in women with existing vertebral fractures over three years [12]. Risedronate and ibandronate are also available as generics.

Denosumab (Prolia), a RANK ligand inhibitor given as a subcutaneous injection every six months, is another option that Affinity may cover with prior authorization. The FREEDOM trial (N=7,868) showed denosumab reduced vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over three years [13]. Denosumab has a different prior authorization pathway and may be approved more readily than Forteo in some cases because its six-month dosing interval and lower cost per year make it more formulary-friendly.

Romosozumab (Evenity), a newer anabolic agent targeting sclerostin, received FDA approval in 2019. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced vertebral fractures by 48% compared to alendronate alone over 24 months [14]. Romosozumab carries a black-box warning for cardiovascular risk, which limits its use in patients with recent myocardial infarction or stroke. Coverage criteria for romosozumab through Affinity are typically even more restrictive than for Forteo.

Eli Lilly offers the Forteo Savings Card program for commercially insured patients, though this program generally excludes Medicaid and Medicare beneficiaries. Patient assistance programs through Lilly's LillyAssist may provide free medication for uninsured or underinsured patients who meet income eligibility requirements [15].

How Long Forteo Treatment Lasts and What Comes After

FDA labeling limits Forteo treatment to 24 months. This cap stems from preclinical studies in rats that showed osteosarcoma development with prolonged high-dose teriparatide exposure, though no increased osteosarcoma risk has been confirmed in human post-marketing surveillance spanning over two decades [1].

The 24-month window matters for insurance coverage because Affinity will not authorize refills beyond this period. After completing Forteo, the standard of care is to transition to an antiresorptive agent (a bisphosphonate or denosumab) to maintain the bone density gains achieved during anabolic therapy. A study published in the Journal of Clinical Endocrinology & Metabolism showed that patients who received alendronate after teriparatide continued to gain BMD at the spine and hip, while those who received placebo lost a significant portion of the bone density gained during teriparatide treatment [16].

The AACE guidelines recommend: "Following a course of anabolic therapy, transition to antiresorptive treatment is mandatory to preserve and extend the skeletal benefits" [2]. Your prescriber should plan the post-Forteo regimen at the start of treatment rather than waiting until the 24-month course ends. Affinity's prior authorization for the follow-on antiresorptive is typically straightforward given the documented clinical history.

Steps to Get Forteo Covered by Affinity Health Plan

A clear process improves your odds of approval. Start by confirming your specific Affinity plan's formulary status for teriparatide. You can do this by calling the member services number on the back of your insurance card or checking Affinity's online formulary lookup tool.

Next, ensure your prescriber has all required documentation ready before submitting the prior authorization: a DXA scan performed within the past two years, imaging of any fragility fractures, a complete medication history showing prior osteoporosis therapy and outcomes, and relevant lab work (serum calcium, vitamin D, renal function). The prescriber should cite specific guideline recommendations from the AACE or the Endocrine Society to justify the request.

If you are a Medicaid managed care member in New York, remember that state law requires Affinity to cover medically necessary medications even if they are not on the preferred drug list, provided the prescriber demonstrates that preferred alternatives are inappropriate for your specific clinical situation. This "override" provision is codified in New York Social Services Law and gives you additional use during the appeal process.

Dr. Andrea Singer, Director of Bone Density at MedStar Georgetown University Hospital and past president of the National Osteoporosis Foundation, has stated: "Insurance barriers to anabolic osteoporosis therapy remain one of the biggest obstacles to reducing fracture rates in high-risk patients. Physicians and patients should be prepared to advocate persistently for appropriate treatment" [7].

Track every submission date, reference number, and communication with Affinity in writing. If your first appeal fails, request an external review through the New York Department of Financial Services within 60 days of the final internal denial.